|
🐜
|
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
39 auth.
P. Ott,
S. Hu-Lieskovan,
B. Chmielowski,
R. Govindan,
A. Naing,
N. Bhardwaj,
K. Margolin,
M. Awad,
M. Hellmann,
Jessica J. Lin,
T. Friedlander,
M. Bushway,
Kristen N Balogh,
Tracey E. Sciuto,
Victoria L. Kohler,
...
S. Turnbull,
Rana H. Besada,
Riley R. Curran,
Benjamin Trapp,
J. Scherer,
A. Poran,
D. Harjanto,
D. Barthelme,
Ying S. Ting,
Jesse Z. Dong,
Yvonne Ware,
Yuting Huang,
Zhengping Huang,
Amy Wanamaker,
Lisa D. Cleary,
M. A. Moles,
K. Manson,
J. Greshock,
Z. Khondker,
E. Fritsch,
Michael S. Rooney,
M. DeMario,
R. Gaynor,
L. Srinivasan
|
8 |
2020 |
8
🐜
|
|
🐜
|
A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.
11 auth.
G. Falchook,
M. Patel,
T. Yap,
K. McEachern,
K. Kuplast-Barr,
L. Utley,
...
Lisa D. Cleary,
Erika L. Manyak,
V. Bozon,
S. Parasuraman,
M. Johnson
|
3 |
2021 |
3
🐜
|
|
🐜
|
Abstract 942: The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: Association with clinical outcomes
25 auth.
S. Hu-Lieskovan,
P. Ott,
A. Naing,
Rana H. Besada,
Samantha J. Gates,
Victoria R. Kohler,
Riley R. Curran,
M. Bushway,
J. Scherer,
Kristen N Balogh,
Tracey E. Sciuto,
Ying S. Ting,
Michael S. Rooney,
D. Harjanto,
Zhengping Huang,
...
Yuting Huang,
Yvonne Ware,
A. Lamb,
Lisa D. Cleary,
M. A. Moles,
R. Gaynor,
M. Goldstein,
L. Brail,
J. Greshock,
L. Srinivasan
|
3 |
2019 |
3
🐜
|
|
🐜
|
An open-label, phase 1b study of NEO-PV-01 with pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous non-small cell lung cancer.
7 auth.
R. Govindan,
M. Awad,
Lisa D. Cleary,
M. A. Moles,
R. Gaynor,
M. Goldstein,
...
D. Spigel
|
2 |
2018 |
2
🐜
|
|
🐜
|
Abstract 5006: Comprehensive gene expression analysis of the tumor microenvironment in patients with advanced cancer treated with a personalized neoantigen vaccine, NEO-PV-01, in combination with anti-PD1
19 auth.
M. Bushway,
Ying S. Ting,
Rana H. Besada,
Tracey E. Sciuto,
Jasmina Prabhakara,
J. Scherer,
Kristen N Balogh,
A. Lamb,
J. Kaplan,
Lisa D. Cleary,
...
M. A. Moles,
S. Church,
Yuqi Ren,
X. Ren,
R. Gaynor,
M. Goldstein,
L. Brail,
J. Greshock,
L. Srinivasan
|
0 |
2019 |
0
🐜
|
|
🐜
|
Abstract LB-147: Comprehensive immune and molecular analysis of two metastatic melanoma patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1: A case study
17 auth.
A. Naing,
P. Ott,
Samantha J. Gates,
J. G. Martinez,
Riley R. Curran,
Victoria L. Kohler,
M. Bushway,
J. Scherer,
D. Barthelme,
Jesse Z. Dong,
...
A. Lamb,
Lisa D. Cleary,
M. A. Moles,
J. Greshock,
R. Gaynor,
M. Goldstein,
L. Srinivasan
|
0 |
2018 |
0
🐜
|
|
🐜
|
Abstract 1836: RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in patient tumors
14 auth.
K. Kuplast-Barr,
Melissa L. Johnson,
Manish R Patel,
T. Yap,
G. Falchook,
P. Lorusso,
R. Abo,
Chang Liu,
Erika L. Manyak,
Lisa D. Cleary,
...
V. Bozon,
S. Parasuraman,
H. Keilhack,
K. McEachern
|
0 |
2022 |
0
🐜
|
